You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting STT3A and STT3B to Block Flavivirus Replication

    SBC: New England Discovery Partners, LLC            Topic: NIAID

    AbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial impact on public health programs that seek to improve outcomes for populations infected with ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections

    SBC: TSRL, INC.            Topic: NIAID

    Abstract In the United Statesskin and soft tissue infectionsSSTIsare one of the most common indications for antibiotic treatmentrepresentingof hospital admissions andmillion doctor visits a yearSSTIs range from selflimiting furuncles and cellulitis to life threatening sepsis and tissue necrosisRecent studies suggest more thanof all SSTIs were caused by staphylococcal or streptococcal speciesin par ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Validation of a Diagnostic Test for Borrelia miyamotoi

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United StatesEurope and AsiaA member of the relapsing fever group of Borreliathis pathogen has been proven to cause most commonly a nonspecificflu like illness with feverfatiguemyalgiaand headacheDisease can be particularly severe and involve the central nervous system in immunocomprom ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Pirenzepine for HIV SN

    SBC: WinSanTor, Inc.            Topic: 101

    PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Treatment for Traumatic Brain Injury

    SBC: Epigen Biosciences, Inc.            Topic: 101

    SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms

    SBC: THERATARGET, INC.            Topic: 106

    NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike proteinKto embolize cerebral aneurysmsThe SELP embolic would reduce the risk of aneurysm rupture while minimizing the risk of recanalization after treatment and providing a platform for del ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. A Unified System for Wireless Optogenetics and Brain Microdialysis for Small Molecules Prototype Development and Validation

    SBC: AMUZA, INC            Topic: 101

    PROJECT SUMMARY While optogenetics is well suited for understanding the dynamic activity of neural circuits the first central theme of the NIH BRAIN Initiative PAR its neurochemical impacts remain largely uncharacterized due to a lack of appropriate tools Given that the predominant mode of cellular interactions is neurochemical commercial development of such tools will fulfill the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Automated electrophysiological analysis of neural circuitry using a novel nano electrode array for intracellular recording of membrane potential

    SBC: CYION TECHNOLOGIES LLC            Topic: 101

    Summary Nervous systems process information by integrating the electrical activity of neurons in complex networks The alterations in the flow of electrical activity through neuronal networks of the brain play a causal role in the pathogenesis and or the appearance of symptoms of neurodegenerative and psychiatric diseases A fundamental goal of BRAIN Initiative is therefore to elucidate how the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a new small molecule therapeutic for the treatment of resistant breast cancer

    SBC: VioMedix, LLC            Topic: 102

    PROJECT SUMMARYABSTRACTBreast cancer is the second leading cause of death in females with cancerInapproximatelynew cases of invasive breast cancer were diagnosedwhere an estimate ofwas expected to succumb to their diseaseIt is estimated that one in eight women will develop breast cancer in their lifetimeBreast cancer is classified into subtypes based on the expression of estrogen receptorERprogest ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government